158 related articles for article (PubMed ID: 22344275)
1. An invariant road to cross-presentation.
Duan F; Srivastava PK
Nat Immunol; 2012 Feb; 13(3):207-8. PubMed ID: 22344275
[No Abstract] [Full Text] [Related]
2. A CD74-dependent MHC class I endolysosomal cross-presentation pathway.
Basha G; Omilusik K; Chavez-Steenbock A; Reinicke AT; Lack N; Choi KB; Jefferies WA
Nat Immunol; 2012 Feb; 13(3):237-45. PubMed ID: 22306692
[TBL] [Abstract][Full Text] [Related]
3. N-terminal functional region of the invariant chain efficiently targets the binding of a CTL epitope to MHC class I molecules during cross-presentation.
Wu C; Zhang DG; Chen FF; Liu XL; Liu SJ; Yu WY
Genet Mol Res; 2014 Apr; 13(2):2438-50. PubMed ID: 24781998
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-restricted antigen processing and presentation.
Pieters J
Adv Immunol; 2000; 75():159-208. PubMed ID: 10879284
[No Abstract] [Full Text] [Related]
5. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.
Germain RN
Cell; 1994 Jan; 76(2):287-99. PubMed ID: 8293464
[No Abstract] [Full Text] [Related]
6. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.
Lin X; Wang X; Capek HL; Simone LC; Tuli A; Morris CR; Reber AJ; Solheim JC
Cancer Immunol Immunother; 2009 May; 58(5):729-36. PubMed ID: 18828016
[TBL] [Abstract][Full Text] [Related]
7. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1.
Treiner E; Duban L; Bahram S; Radosavljevic M; Wanner V; Tilloy F; Affaticati P; Gilfillan S; Lantz O
Nature; 2003 Mar; 422(6928):164-9. PubMed ID: 12634786
[TBL] [Abstract][Full Text] [Related]
8. Invariant chain, a chain of command.
Matza D; Kerem A; Shachar I
Trends Immunol; 2003 May; 24(5):264-8. PubMed ID: 12738421
[No Abstract] [Full Text] [Related]
9. Redirecting soluble antigen for MHC class I cross-presentation during phagocytosis.
Hari A; Ganguly A; Mu L; Davis SP; Stenner MD; Lam R; Munro F; Namet I; Alghamdi E; Fürstenhaupt T; Dong W; Detampel P; Shen LJ; Amrein MW; Yates RM; Shi Y
Eur J Immunol; 2015 Feb; 45(2):383-95. PubMed ID: 25378230
[TBL] [Abstract][Full Text] [Related]
10. The role of endosomes and lysosomes in MHC class II functioning.
Geuze HJ
Immunol Today; 1998 Jun; 19(6):282-7. PubMed ID: 9639994
[No Abstract] [Full Text] [Related]
11. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
Karlsson L
Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
[TBL] [Abstract][Full Text] [Related]
12. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
[TBL] [Abstract][Full Text] [Related]
13. Cross-dressing: an alternative mechanism for antigen presentation.
Campana S; De Pasquale C; Carrega P; Ferlazzo G; Bonaccorsi I
Immunol Lett; 2015 Dec; 168(2):349-54. PubMed ID: 26551033
[TBL] [Abstract][Full Text] [Related]
14. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
15. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways.
Loss GE; Elias CG; Fields PE; Ribaudo RK; McKisic M; Sant AJ
J Exp Med; 1993 Jul; 178(1):73-85. PubMed ID: 8315396
[TBL] [Abstract][Full Text] [Related]
16. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
18. [Construction of hepatitis C virus-NS3 Th1 plasmid vaccine based on MHC class II-associated invariant chain peptide substitution].
Gao M; Wang HP; Lu Y; Zhou Y; Wang YN; Zhan LS; Wang QL
Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):309-10. PubMed ID: 20460057
[No Abstract] [Full Text] [Related]
19. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation.
Frauwirth K; Shastri N
Cell Immunol; 2001 May; 209(2):97-108. PubMed ID: 11446742
[TBL] [Abstract][Full Text] [Related]
20. Positive selection of invariant V alpha 14+ T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells.
Adachi Y; Koseki H; Zijlstra M; Taniguchi M
Proc Natl Acad Sci U S A; 1995 Feb; 92(4):1200-4. PubMed ID: 7862661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
